Moderna (MRNA) has become a focal point for investors after fresh phase 3 data on its cancer vaccine intismeran with Merck's Keytruda, alongside higher 2026 revenue guidance and increased oncology spending.
Despite the positive cancer data and higher 2026 guidance, Moderna’s recent share price has been under pressure, with a 7 day share price return of down 20% and a 1 day move of down 3.6% as investors weigh heavier long term oncology spending against near term enthusiasm.
Stepping back from the week shows a much larger move. The 90 day share price return of about 2.4x and a very large year to date share price gain indicate that momentum has already been powerful, while the 1 year total shareholder return of about 7.7x shows how much potential progress the market may already be factoring in.
Capitalize on the renewed focus on Moderna and oncology by scanning a hand picked group of healthcare and biotech names in the 36 healthcare AI stocks.The recent swing in Moderna now forces a simple question. Are investors reacting to a business that has genuinely shifted, or are expectations just whipping around a story that has already run hard?
Moderna closed at $215.27 against a narrative fair value of $230.15, which frames the current sell off as a pullback rather than a broken story according to LunaRodas, a Simply Wall St Community investor who wrote the narrative.
Revenue guidance tells a related story, though the framing shifted more than the mechanics underneath it. Management had reiterated growth of “up to 10 percent” for the year, hedged explicitly against a possible decline in COVID vaccination rates. That range is now 15 to 25 percent, though Bancel also cites 15 to 20 percent later in the same remarks, a discrepancy nobody on the call flagged. Whichever number holds, the underlying data supports the raise: international revenue of $900 million year-to-date already exceeds everything Moderna delivered internationally in the entire prior year, and the two growth drivers named three months ago, mNEXSPIKE adoption and the UK, Canada and Australia partnerships, are the same two drivers credited for this quarter’s beat. The adjective did not do the work here. The number did, and the adjective followed it.
See why 2 investors see Moderna as 6% undervalued.
At face value, that 6% gap between the fair value of $230.15 and the recent price of $215.27 is small, which places more weight on how much trust you place in the story LunaRodas lays out than on a single headline metric. The bigger takeaway is that the narrative leans on execution around oncology, respiratory vaccines, and raised guidance rather than on sentiment alone.
The narrative also sits alongside Simply Wall St’s own SWS DCF model, which currently marks Moderna as trading at roughly 3.8% below an estimated future cash flow value of $223.83. That extra lens does not replace the narrative, but it shows that a cash flow based approach and a story first approach are both landing in a similar ballpark for now.
Result: Fair Value of $230.15 (UNDERVALUED)
Still, Moderna’s story can wobble quickly if oncology spending weighs more heavily on profitability or if key programs like norovirus and RCC continue to lose clarity.
Find out about the key risks to this Moderna narrative.
The first take on Moderna leaned on fair value estimates that show the shares a little below intrinsic worth. A simple revenue multiple tells a much tougher story. The current P/S of 34.5x is far above the US Biotechs industry at 9.8x and peers at 6.6x, and it also sits well beyond a fair ratio of 6.5x.
That kind of gap leaves less room for error. If the market ever drifts closer to that fair ratio, investors would be relying heavily on future execution to support today’s price. The key issue is which signal investors place more weight on when the story heats up again.See what the numbers say about this price — find out in our valuation breakdown.
If this mix of optimism and concern around Moderna feels familiar, move quickly to stress test the story against the underlying data and sentiment. To weigh both sides of the argument in one place, start with the 2 key rewards and 1 important warning sign.
Round out your watchlist while Moderna’s story plays out by scouting other opportunities that match clear, data driven filters instead of headlines alone.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com